- FDA Rules for Cigarettes Are a Victory for Public Health, for Science (and for the Earth’s Climate?)
- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
First Human Somatic Cell Nuclear Transfer Reported
A San Diego company has announced that it has been able to obtain embryo-like bodies by depositing the nucleus of a human skin cell into a human egg cell that has had its nucleus removed. The process is technically known as somatic cell nuclear transfer (SCNT) or, more simply, nuclear transfer, and is popularly known as cloning.
This process, which was made famous by the sheep clone Dolly about ten years ago, would allow research on stem cells with particular traits, such as gene-linked diseases, depending on the genes of the skin cell donor. The stem cells would be derived from the embryos developed through the cloning procedure. Thus laboratory research on specific genetic complexes associated with certain diseases would be markedly advanced. The stem cell products of SCNT might also be used to treat disorders in the donor, called therapeutic cloning. For example, healthy pancreatic islet cells might be produced that are genetically compatible with a diabetes patient and able to encourage growth of normal cells in the patient’s organ. However, the company has not yet been able to extract stem cells from the embryos.
The company, called Stemagen, said it used 25 human eggs obtained with informed consent to obtain five embryos, a fairly respectable success rate, especially considering the difficulties involved in obtaining human eggs. However, because of the shortage of human eggs, that rate would have to be signficantly improved in order for therapeutic cloning to be a realistic option. The five embryos grew to clusters of between 40 and 72 cells.
The announcement is another in a recent spate of important developments in stem cell biology, including the creation of pluripotent stem cells from human skins cells.
Comments on this article
site yur sources yo….
March 7th, 2010 at 9:53 pm